- Report
- January 2024
- 200 Pages
Global
From €4802EUR$5,000USD£4,134GBP
- Report
- May 2024
- 89 Pages
Global
From €5379EUR$5,600USD£4,631GBP
- Report
- February 2024
- 190 Pages
Global
From €4706EUR$4,900USD£4,052GBP
- Report
- August 2018
- 83 Pages
Global
From €5715EUR$5,950USD£4,920GBP
- Report
- January 2022
- 115 Pages
Global
From €4562EUR$4,750USD£3,928GBP
- Drug Pipelines
- November 2018
- 143 Pages
Global
From €3362EUR$3,500USD£2,894GBP
- Report
- October 2023
- 83 Pages
Global
From €3500EUR$3,904USD£3,119GBP
- Report
- May 2022
- 167 Pages
Global
From €2401EUR$2,500USD£2,067GBP
Myeloproliferative Disorder (MPD) is a type of cancer that affects the bone marrow and blood cells. It is characterized by an overproduction of white blood cells, red blood cells, and platelets. Treatment for MPD typically involves chemotherapy, radiation therapy, and/or targeted therapy. Oncology drugs used to treat MPD include interferon-alpha, hydroxyurea, anagrelide, and ruxolitinib. These drugs are used to reduce the production of abnormal cells, reduce the risk of blood clots, and reduce the risk of infection.
There are several companies that produce and market drugs for the treatment of MPD. These include Novartis, Pfizer, Incyte, and Celgene. Other companies that specialize in oncology drugs include Bristol-Myers Squibb, Merck, and AstraZeneca. Show Less Read more
